From what I remember Daniel saying in the past, AML is the fall-back option should FTO and cardio-protection both fail, which even as a sole indication should still (in his opinion) provide a return of multiples of our current market cap. I expect this is at least one reason that licensing this indication hasn't been pursued.
It could be argued perhaps that this is an overly conservative approach, given that (I assume) we all feel that total failure on both FTO and cardio-protection is (extremely) unlikely.
Ann: Quarterly Activity Report & Appendix 4C, page-42
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.75 |
Change
0.010(0.57%) |
Mkt cap ! $298.0M | |||
| Open | High | Low | Value | Volume |
| $1.73 | $1.83 | $1.73 | $272.0K | 152.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9998 | $1.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.79 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |